Sera Prognostics, Inc., (SERA): Price and Financial Metrics

Sera Prognostics, Inc., (SERA): $8.04

0.18 (-2.19%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

F

Add SERA to Watchlist
Sign Up

Industry: Medical - Services

Industry

C

Ranked

#62 of 64

in industry

SERA Price/Volume Stats

Current price $8.04 52-week high $12.35
Prev. close $8.22 52-week low $1.52
Day low $7.93 Volume 79,297
Day high $8.29 Avg. volume 196,846
50-day MA $9.38 Dividend yield N/A
200-day MA $6.02 Market Cap 262.54M

SERA Stock Price Chart Interactive Chart >


Sera Prognostics, Inc., (SERA) Company Bio


Sera Prognostics, Inc., a health diagnostic company, discovers, develops, and commercializes biomarker tests for the early prediction of preterm birth risk and other complications of pregnancy. It develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.


SERA Latest News Stream


Event/Time News Detail
Loading, please wait...

SERA Latest Social Stream


Loading social stream, please wait...

View Full SERA Social Stream

Latest SERA News From Around the Web

Below are the latest news stories about SERA PROGNOSTICS INC that investors may wish to consider to help them evaluate SERA as an investment opportunity.

Here's Why Sera Prognostics, Inc. (SERA) is a Great Momentum Stock to Buy

Does Sera Prognostics, Inc. (SERA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Yahoo | December 11, 2023

While institutions invested in Sera Prognostics, Inc. (NASDAQ:SERA) benefited from last week's 183% gain, retail investors stood to gain the most

Key Insights Significant control over Sera Prognostics by retail investors implies that the general public has more...

Yahoo | December 7, 2023

Stocks Edge Higher On Hopes Of Soft Economic Landing

Easing labor costs, rising productivity, and a cooling labor market are supporting Wall Street this afternoon.

TalkMarkets.com | December 6, 2023

Why Is Sera Prognostics (SERA) Stock Up 260% Today?

With an oversight board recommending Sera Prognostics halt its clinical study for efficacy, SERA stock soared on the positive implications.

Josh Enomoto on InvestorPlace | December 6, 2023

SERA PROGNOSTICS ANNOUNCES PRIMARY ENDPOINT CRITERIA MET IN PIVOTAL PRIME STUDY INTERIM LOOK - ENROLLMENT TO STOP DUE TO SUCCESS

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the Data Safety Monitoring Board (DSMB) overseeing its pivotal Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study recommended stopping enrollment due to efficacy, reporting that either of the co-primary endpoints met the stoppi

Yahoo | December 6, 2023

Read More 'SERA' Stories Here

SERA Price Returns

1-mo -3.71%
3-mo -13.17%
6-mo 64.08%
1-year 142.90%
3-year N/A
5-year N/A
YTD 34.45%
2023 374.60%
2022 -81.66%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!